Q-omics provides the consensus-scored POTEF-AS1 profile across patient tissues and cancer cell-line models. POTEF-AS1 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, POTEF-AS1 is differentially expressed in 3, with the highest sampling consensus in HNSC. Additionally, POTEF-AS1 RNA expression shows 6,563 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight KICH, HNSC, and COAD as cancer lineages where POTEF-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POTEF-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POTEF-AS1 survival associations across molecular data types. POTEF-AS1 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POTEF-AS1 RNA expression–survival associations across cancer types. High POTEF-AS1 expression shows unfavorable associations in KICH, COAD and BLCA, but favorable associations in BRCA, ESCA and UCS. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for POTEF-AS1 RNA expression.
This table summarizes POTEF-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for POTEF-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POTEF-AS1 shows higher tumor expression in HNSC, BRCA and LUSC. The HNSC box plot shows higher POTEF-AS1 RNA expression in tumor versus normal tissue (log2 FC = +0.050, t-test p = .026).
This table shows molecular features associated with POTEF-AS1 in patient tissues and cancer cell lines. In patient samples, POTEF-AS1 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
